Robert Sullivan, Ph.D.
Senior Director, Preclinical Development
Dr. Sullivan leads the preclinical development programs at BioTheryX which includes all CMC and IND enabling studies. He has extensive experience in Drug Substance (small molecule, peptide) and Drug Product (oral, injectable) manufacturing, Analytical development, process scale-up and validation. He has over 28 years’ experience within the Biotech industry of which 19 have been in CMC. Dr. Sullivan had leadership roles in both small are large companies including Amylin Pharmaceuticals, Boehringer Ingelheim, Heron Therapeutics and NovoMedix. He earned his PhD in Organic Chemistry from the University of California Irvine.